Abstract: The present invention provides methods of treating auto-immune or inflammatory diseases comprising administering an amount of a B7 family protein or derivative thereof to a subject in need thereof.

Abstract: Compositions and methods are disclosed for treating hypomelanotic conditions such as vitiligo and promoting melanogenesis.

Abstract: The present disclosure provides methods for predicting or determining the sensitivity of a cell and/or biological sample obtained from a subject to a DHFR inhibitor including, for example, an antifolate such as Methotrexate or Pemetrexed. Such methods may comprise determining the expression level of one or more miRNAs (e.g., one or more members of the miR-181 and/or miR-143 families) in a cell or biological sample. The methods may be used to determine the responsiveness of a subject to treatment with a DHFR inhibitor.

Abstract: Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen.

Abstract: Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen.

Abstract: The present disclosure relates generally to methods and materials for determining the responsiveness of a subject with a disease or disorder to an inhibitor of a receptor tyrosine kinase including, for example, IGF1R. Such methods may comprise obtaining a biological sample from the subject, assaying the biological sample for one or more PIK3CA mutations, determining if one or more PIK3CA mutations are present in the biological sample, and employing the determination of one or more PIK3CA mutations in the biological sample to predict responsiveness of the subject to the receptor tyrosine kinase inhibitor.

Abstract: Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen.

Abstract: Compositions and methods are disclosed for the treatment of cells, such as keratinocytes and adipocytes, to increase their lipid content and compositions and methods are disclosed for treatment of skin cells to diminish the appearance of blemishes.

Abstract: Compositions and methods are disclosed for treating vitiligo and promoting the formation of collagen.

Abstract: The present disclosure relates generally to methods and materials for determining the responsiveness of a subject with a disease or disorder to an inhibitor of a receptor tyrosine kinase including, for example, IGF1R. Such methods may comprise obtaining a biological sample from the subject, assaying the biological sample for one or more PIK3CA mutations, determining if one or more PIK3CA mutations are present in the biological sample, and employing the determination of one or more PIK3CA mutations in the biological sample to predict responsiveness of the subject to the receptor tyrosine kinase inhibitor.

Abstract: The present disclosure provides methods and compositions for treating a disease or disorder in a subject, the method comprising, administering to the subject a therapeutically effective amount of one or more receptor tyrosine kinase inhibitors and a therapeutically effective amount of one or more inhibitors of the dihydrofolate reductase (DHFR) pathway including, for example, methyltransferase inhibitors.

Abstract: The present disclosure relates to a method, kit and controls for detecting phosphorylated Tyr1248 in the c-erbB-2 protein as a predictor of breast cancer progression and as a predictor of therapeutic efficacy of drugs that inhibit both epidermal growth factor receptor and erbB2 protein kinases.

Abstract: The invention is the method of using the soluble modified receptor erbB3 to treat breast cancer by competitively inhibiting ligands, such as heregulin, from binding to erbB3 tyrosine kinase receptors on cell surfaces.

Abstract: The present invention is a rapid, specific, and sensitive method of detecting mutations in receptor tyrosine kinase genes in formalin fixed tissue embedded in paraffin blocks to detect mutations.

Abstract: This invention provides methods for determining or predicting response to cancer therapy in an individual.

Abstract: Biomarkers may be used in the treatment of cancer, and as an aid in clinical decision making regarding which anti-cancer therapy to use in a particular patient. Described herein are methods of assessing whether a subject with a solid tumor is suitable for treatment with a dual EGFR/erbB2 tyrosine kinase inhibitor, by assessing the relative localization of pERK or pAKT in tumor cells, and/or assessing pre-treatment tumor cell levels of ErbB2.

Abstract: The present invention relates to a panel of targeted therapy markers that can be used in assessing a particular subject's sensitivity to various therapeutic agents and cancer treatments as a means of prognosticating whether a treatment or use of a particular therapeutic agent will result in a clinically positive outcome. Cellular receptors, ligands to those receptors and molecules involved in the programmed cell death pathway are examples of targeted therapy markers that might be used in the present invention.

Abstract: Molecular markers useful in medicine response tests are provided, as an aid in determining whether an individual subject s tumor is responding to treatment with EGF and/or erbB2 inhibitors.

Abstract: The invention provides methods for the detection and quantification of AKT proteins and their activation states in cells or tissue samples. Specifically, the invention provides methods for the detection and quantification of AKT1 or AKT2 proteins or their activated derivatives by combining immunohistochemical assays, calibrated by reference to other immunological, biochemical, or molecular biological assays, with an imaging system to quantify expression or activation levels of these proteins.